DermTech Ret. on assets
What is the Ret. on assets of DermTech?
The Ret. on assets of DermTech, Inc. is -68.96%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on NASDAQ compared to DermTech
What does DermTech do?
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Companies with ret. on assets similar to DermTech
- Hanstone Gold has Ret. on assets of -69.34%
- Next Dynamics has Ret. on assets of -69.30%
- Mint Payments has Ret. on assets of -69.21%
- Antisense Therapeutics has Ret. on assets of -69.08%
- Provention Bio has Ret. on assets of -69.08%
- Skeena Resources has Ret. on assets of -69.04%
- DermTech has Ret. on assets of -68.96%
- INmune Bio has Ret. on assets of -68.94%
- Leaf of Faith Beverage has Ret. on assets of -68.88%
- Vision Marine Technologies has Ret. on assets of -68.86%
- Axovant Gene Therapies has Ret. on assets of -68.72%
- Galecto has Ret. on assets of -68.70%
- Eastern Metals has Ret. on assets of -68.52%